Inside Thermo Fisher’s Stock Performance and Expectations
The Glaring Truth behind Thermo Fisher Scientific's Fundamentals
Stock performance
Thermo Fisher Scientific (TMO) is one of the biggest medical device companies in the United States, having a diversified geographical presence around the world with a leading portfolio of laboratory and analytical products and services. The company was trading at $140.79 as of March 30, 2016, and has a 50-day moving average of $134.31 and a 200-day moving average of $132.57. (For more on the company, check out the series A Must-Read Company Overview of Thermo Fisher Scientific.)
As of March 24, 2016, Thermo Fisher’s stock was trading 18.7% above its 52-week low and 3.2% below its 52-week high. The company’s stock soared ~8.5% since its last quarterly earnings released on January 28, 2016, returning ~5.3% over the last year and outperforming the market as represented by the S&P 500 Index.
Peer stock performance
As of March 24, 2016, Thermo Fisher peers Abbott Laboratories (ABT), Becton Dickinson (BDX), and Agilent Technologies (A) generated returns of -12.9%, 3.1%, -4.1% over the last year. Notably, the Health Care Select Sector SPDR Fund (XLV) invests 2.2% of its portfolio in Thermo Fisher Scientific. XLV has a ~17% exposure to the medical device and technology industry.
Series overview
In this series, we’ll discuss what investors can expect from Thermo Fisher for 2016 and beyond. We’ll also cover analyst estimates and recommendations, factors impacting the expected revenues, earnings and profitability, strategic acquisitions and initiatives, and other fundamentals that affect growth and valuations. Additionally, we’ll look at the company’s emerging market and inorganic growth strategy as well as analyze the acquisition of Affymetrix with a discussion of synergy targets from the 2014 acquisition of Life Technologies.
Let’s start with Thermo Fisher’s revenues.
Browse this series on Market Realist:
